Evidence map›Paper›PMID 39724536›Full record

Observational studyNeurology2025

Blood-Based Biomarkers and Risk of Onset of Mild Cognitive Impairment Over the Short and Long Term.

Anja Soldan, Corinne Pettigrew, Jiangxia Wang, Marilyn S Albert, Kaj Blennow, Tobias Bittner, Abhay Moghekar

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Anja SoldanDepartment of Neurology, The Johns Hopkins University School of Medicine, Baltimore, MD.ORCID 0000-0002-6193-0418
Corinne PettigrewDepartment of Neurology, The Johns Hopkins University School of Medicine, Baltimore, MD.ORCID 0000-0003-4264-275X
Jiangxia WangDepartment of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.ORCID 0000-0002-1715-3981
Marilyn S AlbertDepartment of Neurology, The Johns Hopkins University School of Medicine, Baltimore, MD.ORCID 0000-0002-8167-8985
Kaj BlennowInstitue of Neuroscience and Physiology, University of Gothenburg, Sweden.ORCID 0000-0002-1890-4193
Tobias BittnerF. Hoffmann-LaRoche AG, Basel, Switzerland; and.ORCID 0000-0001-9256-0360
Abhay MoghekarDepartment of Neurology, The Johns Hopkins University School of Medicine, Baltimore, MD.ORCID 0000-0001-9464-1551

Funding

Project 2 MeasurementU19AG033655 · NIA · JOHNS HOPKINS UNIVERSITY · PI Abhay Moghekar · 2014 to 2026
$51.5M
'T V ASSESSMENT - MEMORY DISORDERED PATIENTS'P50AG005146 · NIA · JOHNS HOPKINS UNIVERSITY · PI BANDEEN-ROCHE, KAREN J. · 1985 to 2019
$37.6M
Research Education ComponentP30AG066507 · NIA · JOHNS HOPKINS UNIVERSITY · PI Corinne Pettigrew · 2020 to 2026
$29.3M
NIA NIH HHS P30 AG066507NIA NIH HHS P50 AG005146NIA NIH HHS U19 AG033655
6 · The paper itself

Abstract

BACKGROUND AND

objectivesBlood-based biomarkers of amyloid and tau have been shown to predict Alzheimer disease (AD) dementia. Much less is known about their ability to predict risk of mild cognitive impairment (MCI), an earlier disease stage. This study examined whether levels of blood biomarkers of amyloid (Aβ

methodsCognitively unimpaired participants from the longitudinal observational BIOCARD study provided blood plasma at their baseline evaluation ("baseline 1"). A second "baseline" specimen (collected using slightly different procedures) was evaluated for participants who were still cognitively normal approximately 7 years later. The plasma assays were based on the NeuroToolKit (cobas Elecsys assays, Roche Diagnostics). Cox regression models tested the association of biomarker levels with time to MCI symptom onset, separately for both baselines.

resultsParticipants included 271 individuals at "baseline 1" (mean age = 57.5 years, 60.5% female, including 82 who progressed to MCI/dementia) and 202 individuals at "baseline 2" (mean age = 64.5 years, 62.4% female, including 31 progressors). The mean clinical follow-up was 15.5 years for "baseline 1" and 9.9 years for "baseline 2." For both baselines, lower plasma Aβ DISCUSSION: Results indicate that during preclinical AD, more abnormal blood biomarker levels of amyloid (Aβ

Indexed as

Amyloid beta-PeptidesBiomarkersChitinase-3-Like Protein 1Cognitive DysfunctionPeptide Fragmentstau ProteinsAgedAged, 80 and overDisease ProgressionFemaleGlial Fibrillary Acidic ProteinHumansLongitudinal StudiesMaleMembrane GlycoproteinsMiddle AgedAmyloid beta-Peptidesamyloid beta-protein (1-40)amyloid beta-protein (1-42)BiomarkersCHI3L1 protein, humanChitinase-3-Like Protein 1GFAP protein, humanGlial Fibrillary Acidic ProteinMAPT protein, humanMembrane Glycoproteinsneurofilament protein LNeurofilament ProteinsPeptide FragmentsReceptors, Immunologictau ProteinsTREM2 protein, human

Identifiers

PMID39724536
PMCPMC12492342

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.